Shiraj Sen

Shiraj Sen

Auto-generated profile, based on publicly available information

Shiraj Sen

NEXT Oncology, Dallas, Texas

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
JMJianhui Ma
Jianhui Ma
WLWen Liu
Wen Liu
JLJiali Li
Jiali Li
DKDaehwan Kim
Daehwan Kim
SKSangyub Kim
Sangyub Kim
MLMark R. Lackner
Mark R. Lackner
Genomic instability and accumulation of DNA damage are hallmarks of tumor development and progression. To ensure the maintenance of genomic integrity, cells rely on a coordinated DNA damage response network that regulates cell-cycle progression, including activation of WEE1-dependent cell cycle checkpoints. If DNA damage occurs during replication, the WEE1 checkpoint is activated, thereby preventing the progression of the cell cycle. This allows damaged DNA to be repaired before cells enter mitosis, or if the damage is too extensive, induction of apoptosis. These observations have made WEE1 a promising anticancer therapeutic target. Azenosertib (ZN-c3) is a novel, selective, and orally bioavailable WEE1 inhibitor. The antiproliferative activity of azenosertib on cancer cell lines is consistent with a WEE1-dependent mechanism of action exemplified by reduction of pY15-CDK1 levels and increases in DNA damage markers. Azenosertib further exacerbates the effect of replicative stress and DNA damage by allowing cancer cells to prematurely enter mitosis, leading to mitotic catastrophe and apoptosis. Azenosertib has optimized pharmacokinetic and pharmacodynamic properties, yielding robust tumor growth inhibition in a broad range of tumor models, and is highly effective at delaying the duration of tumor regrowth after cessation of treatment. We have explored various dosing schedules in preclinical efficacy models for azenosertib that preserve antitumor activity with minimal toxicity. Phase I studies with azenosertib as monotherapy have shown preliminary clinical activity in patients with advanced solid tumors. The data presented herein support further studies of azenosertib monotherapy across multiple solid tumor indications.

14 April 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
RPRoberto Carmagnani Pestana
Roberto Carmagnani Pestana
JMJustin Moyers
Justin Moyers
Jason RoszikJason Roszik
Jason Roszik
SSShiraj Sen
Shiraj Sen
DHDavid S. Hong
David S. Hong
VSVivek Subbiah
Vivek Subbiah
Purpose: Developing new therapeutics for any of the more than 100 sarcoma subtypes presents a challenge. After progression from standard therapies, patients with sarcoma may be referred for enrollment in early-phase trials. This study aimed to investigate whether enrollment in biomarker-matched early-phase clinical trials leads to better outcomes for patients with advanced sarcoma. Experimental Design: In this retrospective analysis, investigational treatment characteristics and longitudinal survival outcomes were analyzed in patients with biopsy-confirmed sarcoma enrolled in early-phase trials at MD Anderson Cancer Center from May 2006 to July 2021. Results: Five hundred eighty-seven patients were included [405 soft tissue, 122 bone, 60 gastrointestinal stromal tumor (GIST); median of three prior lines of therapy]. Most common subtypes were leiomyosarcoma (17.2%), liposarcoma (14.0%), and GIST (10.2%). Molecular testing was available for 511 patients (87.1%); 221 patients (37.6%) were treated in matched trials. Overall response rate was 13.1% matched compared with 4.9% in unmatched (P < 0.001); the clinical benefit rate at 6 months was 43.9% vs. 19.9% (P < 0.001). Progression-free survival was longer for patients in matched trials (median, 5.5 vs. 2.4 months; P < 0.001), and overall survival was also superior for patients in matched trials (median, 21.5 vs. 12.3 months; P < 0.001). The benefit of enrollment in matched trials was maintained when patients with GIST were excluded from the analysis. Conclusions: Enrollment in biomarker-matched early-phase trials is associated with improved outcomes in heavily pretreated patients with metastatic sarcoma. Molecular testing of tumors from patients with advanced sarcoma and enrollment in matched trials is a reasonable therapeutic strategy.

9 December 2021 in ONCOLOGY
Verified
Journal Article
Open access
PDF file
CCChristine Chung
Christine Chung
RGRachael Galvin
Rachael Galvin
EAElla Achenbach
Ella Achenbach
ODOliwier Dziadkowiec
Oliwier Dziadkowiec
SSShiraj Sen
Shiraj Sen
Background:, Molecular profiling is being explored in pancreatic adenocarcinoma (PDAC) as a tool to assist with early detection, prognosis, and patient selection in targeted therapy clinical trials. Due to the challenges and risks of traditional tissue biopsies in pancreatic adenocarcinoma, the utility of blood-based molecular profiling is now being explored more broadly. However, given its novelty, what value blood-based molecular profiling may provide to oncologists caring for individuals with PDAC remains unknown. Herein, we characterize the mutational landscape of metastatic PDAC using blood-based circulating tumor DNA (ctDNA) collected in patients with refractory, metastatic PDAC who were referred to an oncology drug development unit in Denver, Colorado, between August 2014 and May 2019. Methods:, We retrospectively analyzed results of blood-based molecular profiling that was performed on 77 consecutive patients with metastatic PDAC who underwent Guardant-360 testing for whom results were available. Results:, In our data set, 55% of patients (41/77) were men, median (SD) age was 66 (9.3) years (range, 44-83). Of 77 patients, 34 (44%) had 1 or more somatic alterations. Variants reported as being of unknown significance were not included in the analyses. The total number of alterations were 119 (nonunique) and 96 (unique). The median number of alterations per patient was 3 and the median mutant allele frequency was 0.5%. ,TP53, was the most commonly altered gene (29 unique alterations), followed by ,KRAS, (27 unique alterations). Of the patients with any alteration, 34% had 1 or more actionable alterations that could be potentially targeted in a clinical trial. Conclusions:, Detection of genomic alterations in ctDNA from patients with metastatic PDAC is feasible and reveals a wide range of genomic alterations, the actionability of which is being explored in clinical trials. Further investigation is needed to determine the extent to which blood-based molecular profiling can provide clinical utility in helping to select patients into clinical trials and determine its impact on survival. Keywords:, molecular profiling, ctDNA, pancreatic adenocarcinoma

3 April 2024
Verified
Other
Open access
RPRoberto Carmagnani Pestana
Roberto Carmagnani Pestana
JMJustin Moyers
Justin Moyers
Jason RoszikJason Roszik
Jason Roszik
SSShiraj Sen
Shiraj Sen
DHDavid S. Hong
David S. Hong
VSVivek Subbiah
Vivek Subbiah
Treemap of most common drug mechanisms for patients treated in biomarker-matched studies.

1 May 2023
Verified
Other
Open access
RPRoberto Carmagnani Pestana
Roberto Carmagnani Pestana
JMJustin Moyers
Justin Moyers
Jason RoszikJason Roszik
Jason Roszik
SSShiraj Sen
Shiraj Sen
DHDavid S. Hong
David S. Hong
VSVivek Subbiah
Vivek Subbiah
Treemap of most common drug mechanisms for patients treated in biomarker-matched studies.

1 May 2023
Verified
Other
Open access
RPRoberto Carmagnani Pestana
Roberto Carmagnani Pestana
JMJustin Moyers
Justin Moyers
Jason RoszikJason Roszik
Jason Roszik
SSShiraj Sen
Shiraj Sen
DHDavid S. Hong
David S. Hong
VSVivek Subbiah
Vivek Subbiah
Summary of response outcomes across subgroups